NEOGENOMICS INC — Form 10-Q
Filed October 28, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 72/100
What the filing says
On October 2, 2026 effective January 4, 2027, NeoGenomics amended employment agreements for two executives and terminated a third. Anthony Zook transitions from CEO to Executive Chairman with $400,000 base salary and $3,000,000 target annual equity (down from prior CEO terms). Warren Stone becomes new CEO with $850,000 base salary, $850,000 target bonus (100% of base), and $8,000,000 target annual equity. Alicia Olivo (EVP General Counsel) separated October 2, 2026 receiving 12 months base salary continuation ($564,000), one-time bonus of $338,400, 12 months COBRA, and accelerated vesting of 12-month time-based equity grants.
Why this rating
Leadership restructuring is material (CEO role change, new CEO hire, GC departure) but both Zook and Stone compensation packages suggest continuity; total severance to Olivo (~$1.1M cash plus equity acceleration) is ~0.16% of $680M market cap—manageable. Watch Stone's $8M equity target and potential executive stability risk.
Price action (we called it neutral)
before filing · preread $18.08 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.